Your browser doesn't support javascript.
loading
Genetic factors affecting survival in Japanese patients with sporadic amyotrophic lateral sclerosis: a genome-wide association study and verification in iPSC-derived motor neurons from patients.
Nakamura, Ryoichi; Tohnai, Genki; Nakatochi, Masahiro; Atsuta, Naoki; Watanabe, Hirohisa; Ito, Daisuke; Katsuno, Masahisa; Hirakawa, Akihiro; Izumi, Yuishin; Morita, Mitsuya; Hirayama, Takehisa; Kano, Osamu; Kanai, Kazuaki; Hattori, Nobutaka; Taniguchi, Akira; Suzuki, Naoki; Aoki, Masashi; Iwata, Ikuko; Yabe, Ichiro; Shibuya, Kazumoto; Kuwabara, Satoshi; Oda, Masaya; Hashimoto, Rina; Aiba, Ikuko; Ishihara, Tomohiko; Onodera, Osamu; Yamashita, Toru; Abe, Koji; Mizoguchi, Kouichi; Shimizu, Toshio; Ikeda, Yoshio; Yokota, Takanori; Hasegawa, Kazuko; Tanaka, Fumiaki; Nakashima, Kenji; Kaji, Ryuji; Niwa, Jun-Ichi; Doyu, Manabu; Terao, Chikashi; Ikegawa, Shiro; Fujimori, Koki; Nakamura, Shiho; Ozawa, Fumiko; Morimoto, Satoru; Onodera, Kazunari; Ito, Takuji; Okada, Yohei; Okano, Hideyuki; Sobue, Gen.
  • Nakamura R; Department of Neurology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
  • Tohnai G; Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Nakatochi M; Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Atsuta N; Division of ALS Research, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
  • Watanabe H; Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Ito D; Department of Neurology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
  • Katsuno M; Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Hirakawa A; Department of Neurology, Fujita Health University, Toyoake, Aichi, Japan.
  • Izumi Y; Brain and Mind Research Center, Nagoya University, Nagoya, Aichi, Japan.
  • Morita M; Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Hirayama T; Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Kano O; Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Kanai K; Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
  • Hattori N; Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Taniguchi A; Division of Neurology, Department of Internal Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
  • Suzuki N; Department of Neurology, Toho University Faculty of Medicine, Ota-ku, Tokyo, Japan.
  • Aoki M; Department of Neurology, Toho University Faculty of Medicine, Ota-ku, Tokyo, Japan.
  • Iwata I; Department of Neurology, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Yabe I; Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan.
  • Shibuya K; Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan.
  • Kuwabara S; Department of Neurology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
  • Oda M; Department of Neurology, Tohoku University School of Medicine, Sendai, Miyagi, Japan.
  • Hashimoto R; Department of Neurology, Tohoku University School of Medicine, Sendai, Miyagi, Japan.
  • Aiba I; Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
  • Ishihara T; Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
  • Onodera O; Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Yamashita T; Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Abe K; Department of Neurology, Vihara Hananosato Hospital, Miyoshi, Hiroshima, Japan.
  • Mizoguchi K; Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Aichi, Japan.
  • Shimizu T; Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Aichi, Japan.
  • Ikeda Y; Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.
  • Yokota T; Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.
  • Hasegawa K; Department of Neurology, Okayama University Graduate School of Medicine, Okayama, Japan.
  • Tanaka F; Department of Neurology, Okayama University Graduate School of Medicine, Okayama, Japan.
  • Nakashima K; Department of Neurology, National Hospital Organization Shizuoka Medical Center, Shizuoka, Japan.
  • Kaji R; Department of Neurology, Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan.
  • Niwa JI; Department of Neurology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
  • Doyu M; Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
  • Terao C; Division of Neurology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan.
  • Ikegawa S; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
  • Fujimori K; Department of Neurology, National Hospital Organization, Matsue Medical Center, Matsue, Shimane, Japan.
  • Nakamura S; Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Ozawa F; Department of Neurology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
  • Morimoto S; Department of Neurology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
  • Onodera K; Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan.
  • Ito T; Laboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan.
  • Okada Y; Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Okano H; Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Sobue G; Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
J Neurol Neurosurg Psychiatry ; 94(10): 816-824, 2023 10.
Article en En | MEDLINE | ID: mdl-37142397
ABSTRACT

BACKGROUND:

Several genetic factors are associated with the pathogenesis of sporadic amyotrophic lateral sclerosis (ALS) and its phenotypes, such as disease progression. Here, in this study, we aimed to identify the genes that affect the survival of patients with sporadic ALS.

METHODS:

We enrolled 1076 Japanese patients with sporadic ALS with imputed genotype data of 7 908 526 variants. We used Cox proportional hazards regression analysis with an additive model adjusted for sex, age at onset and the first two principal components calculated from genotyped data to conduct a genome-wide association study. We further analysed messenger RNA (mRNA) and phenotype expression in motor neurons derived from induced pluripotent stem cells (iPSC-MNs) of patients with ALS.

RESULTS:

Three novel loci were significantly associated with the survival of patients with sporadic ALS-FGF1 at 5q31.3 (rs11738209, HR=2.36 (95% CI, 1.77 to 3.15), p=4.85×10-9), THSD7A at 7p21.3 (rs2354952, 1.38 (95% CI, 1.24 to 1.55), p=1.61×10-8) and LRP1 at 12q13.3 (rs60565245, 2.18 (95% CI, 1.66 to 2.86), p=2.35×10-8). FGF1 and THSD7A variants were associated with decreased mRNA expression of each gene in iPSC-MNs and reduced in vitro survival of iPSC-MNs obtained from patients with ALS. The iPSC-MN in vitro survival was reduced when the expression of FGF1 and THSD7A was partially disrupted. The rs60565245 was not associated with LRP1 mRNA expression.

CONCLUSIONS:

We identified three loci associated with the survival of patients with sporadic ALS, decreased mRNA expression of FGF1 and THSD7A and the viability of iPSC-MNs from patients. The iPSC-MN model reflects the association between patient prognosis and genotype and can contribute to target screening and validation for therapeutic intervention.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Células Madre Pluripotentes Inducidas / Esclerosis Amiotrófica Lateral Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Células Madre Pluripotentes Inducidas / Esclerosis Amiotrófica Lateral Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article